AEROSOL PRESSURIZED INHALATION DELIVERY DEVICE AND METHODS FOR MANUFACTURE AND USE OF THE SAME
20230329354 · 2023-10-19
Inventors
Cpc classification
A61M15/009
HUMAN NECESSITIES
A24B15/167
HUMAN NECESSITIES
A61M15/06
HUMAN NECESSITIES
A61M2205/586
HUMAN NECESSITIES
International classification
A61M15/06
HUMAN NECESSITIES
Abstract
The present invention improves and enhances the delivery of one of an aerosolized or micellized formula by use of an aerosol pressurized inhalation delivery device. The device may include one or more replaceable or reusable components, including but not limited to a canister and a battery. Methods for using the device to deliver a controlled dosage via the delivery device are also described herein.
Claims
1. A pressurized inhalation delivery device comprising: a canister containing a micellized liquid formula; a metered valve coupled to the canister; an actuator having actuator discharge; the actuator positioned adjacent to the metered valve; a propellant residing within the aluminum canister; the canister residing within a receptacle housing; and the actuator coupled to the receptacle housing.
2. The pressurized inhalation delivery device of claim 1 further comprising an actuator discharge childproof safety guard that fits over the actuator.
3. The pressurized inhalation delivery device of claim 1, wherein the micellized liquid formula comprises at least a micellized liquid nicotine formula.
4. The pressurized inhalation delivery device of claim 1, wherein the micellized liquid formula comprises at least a micellized cannabidiol.
5. The pressurized inhalation delivery device of claim 1, wherein the micellized liquid formula comprises at least a micellized tetrahydrocannabinol.
6. The pressurized inhalation delivery device of claim 1, wherein a predetermined volume of micellized liquid formula is delivered through the actuator discharge with each activation of the actuator.
7. The pressurized inhalation delivery device of claim 6, wherein the predetermined volume of micellized liquid formula is in the range of 50 to 100 microliters.
8. The pressurized inhalation delivery device of claim 6, wherein the predetermined volume of micellized liquid formula is 100 microliters.
9. The pressurized inhalation delivery device of claim 6, wherein the predetermined volume of micellized liquid formula is 65 microliters.
10. The pressurized inhalation delivery device of claim 6, wherein the micellized liquid formula comprises at least a nicotine salt.
11. A method of delivery a nano mist micellized liquid formula, comprising: coupling a metered valve on a canister containing micellized liquid formula; placing the canister and metered valve into a receptacle housing; positioning an actuator above the metered valve; activation the actuator by pressing actuator against the metered valve; piercing a diaphragm on the canister with a valve stem associated with the metered valve; delivering, under pressure, a volume of micellized liquid formula from the canister, through the metered valve, into an expansion chamber; delivering the volume of micellized liquid formula from the expansion chamber through a discharge nozzle.
12. The method of claim 11, wherein the delivery step comprises delivering at least one of a micellized liquid nicotine, micellized liquid cannabidiol, micellized liquid tetrahydrocannabinol, and a nicotine salt.
13. The method of claim 11, wherein the method further comprises placing a safety guard about the actuator to prevent further activation.
14. The method of claim 11, wherein the volume of micellized liquid formula is 100 microliters.
15. The method of claim 11, wherein the volume of micellized liquid formula is 65 microliters.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Many aspects of the disclosure can be better understood with reference to the following drawings. While several implementations are described in connection with these drawings, the disclosure is not limited to the implementations disclosed herein. On the contrary, the intent is to cover all alternatives, modifications, and equivalents.
[0029] In certain instances, details that are not necessary for an understanding of the disclosure or that render other details difficult to perceive may have been omitted. It should be understood, of course, that the disclosure is not necessarily limited to the particular embodiments illustrated in the following Figures. In the drawings:
[0030]
[0031]
[0032]
[0033]
[0034]
[0035]
[0036]
[0037]
[0038]
[0039]
[0040]
[0041]
[0042]
[0043]
[0044] It should be understood that the drawings are not meant to be and/or are not necessarily to scale.
[0045] For ease of reference, the following is a listing of components depicted in the drawing figures, some of which are described in greater detail herein:
TABLE-US-00001 100 aerosol inhaler delivery device 102 Actuator 104 actuator mouthpiece 106 actuator discharge area 108 actuator discharge nozzle 110 actuator discharge channel 112 actuator valve sleeve 114 actuator discharge finger slide control 116 actuator discharge finger slide control grip ridges 118 actuator receptacle locking clip 120 actuator discharge finger slide control child proof safety guard 122 child proof safety guard channel locks 124 child proof safety guard plastic compression clip 126 child proof safety guard grips 128 metered valve 130 metered valve stem 132 metered valve internal gasket 134 metered valve external gasket 136 metered valve mounting cup 138 metered valve spring 140 metered valve metering chamber 142 metered valve dip tube 144 receptacle housing 146 receptacle housing actuator rim 148 receptacle housing finger slide control channels 150 receptacle actuator locking edge 152 receptacle canister security ridges 154 receptacle cylindrical grips 156 aluminum canister 158 aluminum canister lip 160 aluminum canister throat 162 aluminum canister rim 164 liquid propellant 166 micellized liquid nicotine formula 168 air pocket
DETAILED DESCRIPTION
[0046] The following disclosure is directed to various embodiments, including those depicted in
[0047] The aerosol pressurized inhalation delivery device eliminates the use of a power source or battery which as used in prior art devices has been known to explode without warning and cause serious injuries including burns, broken bones or even death. The alternative use of a propellant, such as pharma grade 1,3,3,3, -Tetrafluropropene, HFO 1234ze, which is chlorofluorocarbon free and approved by the FDA for use in metered-dose inhalers for the treatment of asthma and other pulmonary obstructive diseases, eliminates the aforementioned safety concerns.
[0048] Placing the aluminum canister into the receptacle housing protects the aluminum canister from impact and allows the actuator to be positioned over the receptacle housing and locked into a secure position via the actuator receptacle locking clip and receptacle actuator locking edge.
[0049] An actuator discharge finger slide control child proof safety guard can be snapped into position over the receptacle housing finger slide control channels eliminating the ability to depress the actuator discharge finger slide control downward providing a child proof aerosol pressurized inhaler deliver device.
[0050] The metered valve is preferably crimped onto the aluminum canister with, for example, a metal crimping collette, which couples the metered valve mounting cup of the metered valve against the rim of the aluminum canister. The crimp or an equivalent connector securely holds the metered valve onto the aluminum canister which once gassed can maintain, by way of example but not limitation, approximately 75 psi (pounds per square inch) pressure inside the aluminum canister.
[0051] The actuator is preferably made from high quality plastic or resinous material and contains a discharge finger slide control that once depressed activates the metered valve and delivers an exact volume of micellized liquid nicotine formula to the user through the mouthpiece. The actuator, once fully depressed downward on the metered valve, allows the metered valve’s valve stem to be pushed downward into the canister. The micellized liquid nicotine formula is thereby forced, under approximately 72 psi, through the metering chamber and into the expansion chamber. Once the volume of micellized liquid nicotine formula is passed into the expansion chamber, the volume is delivered through the nano mist discharge nozzle.
[0052] The volume of liquid micellized formulation delivered with each activation of the actuator is preferably within the range of 50 to 100 microliters. In one embodiment, the volume is precisely controlled at 100 microliters by utilizing a metered valve configured to release 100 microliters. In another embodiment, the volume is precisely controlled at 65 microliters. According to one particular aspect, the method of delivering a known volume of micellized liquid nicotine formula is as follows: once the valve stem has been fully depressed, a valve stem side piercing passes through a diaphragm. The volume of micellized liquid nicotine formula enters into the metering chamber, which includes a precise, controlled volume of micellized liquid nicotine formula and propellant based on the configuration of metered valve.
[0053] From the first actuation until the last actuation, the pressure in the cannister remains constant allowing a controlled, consistent and precise dose of liquid micellized formula and propellant to be expelled through the actuators discharge nozzle.
[0054] In one aspect, the combination of the micellized liquid nicotine formula and propellant, which in one embodiment may be a propellant known commercially as HFA 134a, becomes miscible, visibly clear, having a viscosity similar to water, homogenous mixture, which makes it easier to deliver a precise metered dose of the combined micellized liquid nicotine formula and propellant through the actuator discharge nozzle.
[0055] In embodiments, the nicotine formula is preferably micellized, a phase separation of water from oil. This process, referred to herein as micellization, converts an otherwise oil-based product and their ingredients and making them bio-absorbable or “bio available” to the body, without changing their molecular form and structure.
[0056] Through research and experimentation, the applicant has found that micelles formulated, full spectrum hemp oil (“FSHO”) has demonstrated significantly more bioavailability than non-micelles, unformulated hemp-based oils. This means that the FSHO, using micelle technology is more effective, delivering better than 85% absorption to the body, GI tract and/or skin, with a quicker onset than that of traditional, lower dose, FSHO based, or Cannabidiol based products. The same will apply to Tetrahydrocannabinol oil based micellized formulas.
[0057] The spirit of this disclosure, in one particular aspect, is to eliminate the use of cartridges or reservoirs or pods, heating elements and power sources or batteries in prior art devices, such as vape units, and to replace the corresponding formulas containing nicotine, flavorings, and propylene glycol with a safer known dispensed micellized liquid nicotine formula that dramatically decreases the nicotine percentage oral uptake, delivers better absorption to the body, and helps minimize the known threats of cancer to the user.
[0058] E-cigarette’s use of a battery, the most common called “18650” batteries, heat up the nicotine formula, flavorings and other chemicals and turn them into a vapor the user can breathe. This vapor can contain formaldehyde, heavy metals and other particles that can cause cancer and loge themselves in the users’ deepest parts of the lungs. The present disclosure eliminates the battery or power supply required by e-cigarettes and vaping devices.
[0059] In the “News in Health” article presented by the NIH, National Institute of Health, https://newsinhealth.nih.gov/2020/05/risks-vaping, the risk of vaping is described and acknowledgment is made that “Studies suggest nicotine vaping may be less harmful than traditional cigarettes when people who regularly smoke switch to them as a complete replacement. But nicotine vaping could still damage your health, according to the NIH, because a person must necessarily inhale propylene glycol, vegetable glycerin, and flavorants that were meant to be eaten but not inhaled, not to mention nicotine. When vaping, all of those chemicals are heated up by the power supply and reactor, which may cause those components to turn into other potentially dangerous chemicals.
[0060] An object of this disclosure, in another aspect, is to create a safer aerosol pressurized inhalation delivery device compared to smoking or vaping using similar components to those employed in pressurized metered dose inhalers, pMDI’s, and having a micellized liquid nicotine formula that once inhaled into the lungs delivers greater absorption to the body and significantly lowers the percentage of nicotine inhaled while providing a similar feeling of pleasure for the user.
[0061] Various aspects of the present disclosure are shown in
[0062]
[0063]
[0064]
[0065]
[0066]
[0067]
[0068]
[0069]
[0070]
[0071]
[0072]
[0073]
[0074]
[0075] With respect to the embodiments described above, it is expressly understood that such embodiments may be incorporated for use in practicing the novel methods described herein. In certain embodiments, those methods may comprise greater or fewer steps than as described above. By way of example, but not limitation, one step for use with the various embodiments described above may comprise the step of removing and replacing the canister or securing a safety guard, with different steps included in the method of operation provided accordingly. Thus, variations on this and other steps, and the inclusion or exclusion of additional steps described herein, are expressly contemplated by the present disclosure.
[0076] It is expressly understood that where the term “consumer” has been used to describe the various embodiments of the disclosure, the term should not be construed as limiting in any way. For instance, a consumer could be a human user or, in a veterinary application, an animal. Therefore, it is intended that the device and methods described herein apply equally to veterinary science as they would if practiced on a human being. The apparatus and methods described herein therefore have application beyond controlled dosage of nicotine, by way of example.
[0077] The foregoing discussion of the disclosure has been presented for purposes of illustration and description. The foregoing is not intended to limit the disclosure to the form or forms disclosed herein. In the foregoing Detailed Description for example, various features of the disclosure are grouped together in one or more embodiments for the purpose of streamlining the disclosure. This method of disclosure is not to be interpreted as reflecting an intention that the claimed disclosure requires more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive aspects lie in less than all features of a single foregoing disclosed embodiment. Thus, the following claims are hereby incorporated into this Detailed Description, with each claim standing on its own as a separate preferred embodiment of the disclosure.
[0078] The present inventions, in various embodiments, include components, methods, processes, systems and/or apparatuses substantially as depicted and described herein, including various embodiments, subcombinations, and subsets thereof. Those of skill in the art will understand how to make and use the present inventions after understanding the present disclosure. The present inventions, in various embodiments, include providing devices and processes in the absence of items not depicted and/or described herein or in various embodiments hereof, including in the absence of such items as may have been used in previous devices or processes, e.g., for improving performance, achieving ease and\or reducing cost of implementation.
[0079] Moreover, though the present disclosure has included description of one or more embodiments and certain variations and modifications, other variations and modifications are within the scope of the disclosure, e.g., as may be within the skill and knowledge of those in the art, after understanding the present disclosure. For further illustration, the information and materials supplied with the provisional application from which this application claims priority is expressly made a part of this disclosure and incorporated by reference herein in their entirety. This form of disclosure, therefore, is intended to obtain rights which include alternative embodiments to the extent permitted, including alternate, interchangeable and/or equivalent structures, functions, ranges or steps to those claimed, whether or not such alternate, interchangeable and/or equivalent structures, functions, ranges or steps are disclosed herein, and without intending to publicly dedicate any patentable subject matter.